エドガーで原本を確認する
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
James Ford
|
|
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature of
the transaction
|
The grant of options over Ordinary Shares pursuant to the
Company's Share Save Plan 2022
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.19
|
643
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2025-11-28
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
David Redfern
|
|
|
b)
|
Position/status
|
President, Corporate Development
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature of
the transaction
|
The grant of options over Ordinary Shares pursuant to the
Company's Share Save Plan 2022
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.19
|
643
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2025-11-28
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Victoria Whyte
|
|
|
b)
|
Position/status
|
SVP & Company Secretary
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature of
the transaction
|
The grant of options over Ordinary Shares pursuant to the
Company's Share Save Plan 2022
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.19
|
643
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2025-11-28
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: December
01, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|